Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
621-640 of 998 trials

Targeted Therapies for Moderate to Severe Crohn’s Disease

We are studying new targeted treatments for adults with moderate to severe Crohn’s disease. The goal is to evaluate their safety and effectiveness in managing this condition.

Crohn's Disease3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Ulcerative Colitis: RO7790121 Treatment Study

We are studying a new treatment for people with moderately to severely active ulcerative colitis to see if it can help induce remission. The trial will also assess its safety and impact on symptoms and quality of life.

Ulcerative ColitisConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Major Depression: Samyr® Tablet Study

We are investigating whether Samyr® tablets can improve symptoms in patients with major depressive disorder who are not fully responding to their current treatment. The study compares Samyr® to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

NY-ESO-1 T-Cells for Synovial Sarcoma and Liposarcoma

We are studying genetically engineered T cells in patients with synovial sarcoma and myxoid/round cell liposarcoma. The goal is to see if this treatment is effective and safe for those with specific tumor markers.

Myxoid and Round Cell LiposarcomaSynovial SarcomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Cryptogenic Stroke: STOP Trial on Blood Thinners

We are studying whether stopping blood thinners is as safe as continuing them for young people after a stroke with no known cause. This research may help understand the best approach to prevent future heart problems.

Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Head and Neck Cancer: New Drug Combinations

We are studying a new combination of drugs for patients with recurrent or metastatic head and neck cancer. The goal is to see if this combination works better than the current treatment options.

Recurrent Head and Neck Squamous Cell CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Multifocal Motor Neuropathy: DNTH103 Treatment Study

We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.

Multifocal Motor Neuropathy1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Hypochondroplasia: Vosoritide Treatment Study

We are testing a new medication, vosoritide, to see if it helps children with hypochondroplasia grow taller compared to a placebo. The study aims to evaluate its effects on growth velocity and height.

Hypochondroplasia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatrics

Multiple Sclerosis: Personalized Ocrelizumab Treatment

We are studying whether a tailored dosing of ocrelizumab is as effective as the standard treatment in managing relapsing remitting multiple sclerosis. This trial aims to improve treatment personalization for better disease control.

Multiple Sclerosis>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurology

Severe Influenza: Dexamethasone vs. Placebo

We are studying whether dexamethasone can help patients with severe influenza recover better than a placebo. The trial will assess hospitalization rates, safety, and other health impacts.

H1N1 Influenza>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Fungal Nail Infection: MOB015B Solution for Kids

We are studying a new topical solution for treating mild to moderate fungal infections of the nail in children aged 6 to 17. The goal is to see how well it works and how safe it is.

Distal Subungual Onychomycosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyInfectious DiseasesPediatrics

Advanced Gastric Cancer: [18F]AlF-FAPI-74 PET/CT Study

We are testing a new imaging method to improve the staging of advanced gastric cancer. This study aims to see if it can reduce the need for invasive procedures while providing accurate diagnostic information.

Advanced Gastric CancerEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal MedicineOncology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Alternative Antibiotics for Resistant UTIs

We are testing new oral antibiotics for patients with febrile urinary tract infections caused by resistant bacteria. The goal is to see if these alternatives are as safe as current treatments.

Urinary Tract Infection (UTI) from Resistant Bacteria>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInfectious DiseasesUrology

Crohn's and Colitis: Stopping Anti-TNF Treatment

We are studying if specific markers can help identify patients who can safely stop their anti-TNF treatment while in remission. This may help tailor treatment plans for better health outcomes.

Ulcerative ColitisCrohn's Disease>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics